# US 2013/0158122 A1 · EP2 Agonist from Non-Prostanoid Structures Designed as PGE2 Antagonists

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0158122 A1
- Document ID: US20130158122A1
- Status: Published application
- Kind: A1
- Application number: 13/768,994
- Filed: 2013-02-15
- Published: 2013-06-20
- Earliest claimed: 2010-05-19
- Assignees: Allergan, Inc.
- Inventors: David F. Woodward; Jenny W. Wang
- Web page: https://patentgrep.com/patent/US20130158122A1

## CPC

- A61K 31/192: having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid {(cannabinoids A61K31/658)}
- A61P 27/02: Ophthalmic agents
- A61P 27/06: Antiglaucoma agents or miotics
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C07C 235/60: having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS

## Abstract

A method of treating ocular hypertension, lowering intraocular pressure, pain or inflammation, comprising administering to a mammal a pharmaceutical composition of an EP2-receptor agonist represented by

## Claims

### Claim 1

A method of treating one of the following conditions selected from the group consisting of ocular hypertension, lowering intraocular pressure, pain, and inflammation, the method comprising administering to a mammal in need of such treatment a pharmaceutical composition comprising a compound represented by:

### Claim 2 (depends on 1)

The method of claim 1, wherein the composition comprises a pharmaceutically acceptable salt of compound

### Claim 3 (depends on 1)

The method of claim 1 , wherein the composition comprises a pharmaceutically acceptable ophthalmic emulsion of compound
